Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Catherine Wu
Brigham and Women's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Neon Therapeutics
Payment for services (e.g., consulting fees, honoraria, paid authorship)
The goal of Neon Therapeutics is to develop and implement immunotherapy treatments to target personal tumor neoantigens. The grant proposes to conduct a Phase II trial in which AML patients with high risk features who undergo allogeneic transplantation in remission will undergo post-transplant vaccination with donor DC/AML fusions alone or in conjunction with HMA. The proposed work will assess the immunological response following post-transplant vaccination alone or with HMA, and will use a murine leukemia model to test the effects of second generation checkpoint inhibitors, RGMb and TIM3, alone or in combination with PD-1 blockade on DC/AML fusion vaccine response. The results of this Work, specifically the neoantigen-related work, could directly and significantly impact the business of Neon and be of scientific relevance to its ongoing development efforts.
SPORE in Myeloid Malignancies
Overall Project Narrative Myeloid malignancies are cancers that caused by overgrowth of bone marrow stem cells, leading to abnormal production of blood cells. Understanding the mechanisms that allow such overgrowth will provide an avenue to develop therapeutic strategies that specifically inhibiting the abnormal pathways and/or aid the patient's own immune system to recognize these abnormal cells. Research in the SPORE will develop new therapies that could be more specifically effective than current cytotoxic drugs.
Filed on January 17, 2018.
Tell us what you know about Catherine Wu's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Catherine Wu”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Catherine Wu | Dana Farber Cancer Inst | Conflict of Interest | Neon Therapeutics, Inc. | $100,000 - $149,999 |
| Catherine Wu | Beth Israel Deaconess Medical Center | Conflict of Interest | Neon Therapeutics | $100,000 - $149,999 |
| Catherine Wu | Dana Farber Cancer Inst | Conflict of Interest | Neon Therapeutics | $100,000 - $149,999 |
| Catherine Wu | Dana Farber Cancer Inst | Conflict of Interest | Neon Therapeutics | $40,000 - $59,999 |
| Catherine Wu | Dana Farber Cancer Inst | Conflict of Interest | Neon Therapuetics | Value cannot be readily determined |
| Catherine Wu | Dana Farber Cancer Inst | Conflict of Interest | Neon Therapeutics, Inc. | >$600,000 |
| Catherine Wu | Brigham and Women's Hospital | Conflict of Interest | Neon Therapeutics | Value cannot be readily determined |
| Catherine Wu | Dana Farber Cancer Inst | Conflict of Interest | Neon Therapuetics | $100,000 - $149,999 |
| Catherine Wu | Dana Farber Cancer Inst | Conflict of Interest | Neon Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.